152 related articles for article (PubMed ID: 15792762)
1. Recombinant factor VIIa for the treatment of severe postoperative and traumatic hemorrhage.
Khan AZ; Parry JM; Crowley WF; McAllen K; Davis AT; Bonnell BW; Hoogeboom JE
Am J Surg; 2005 Mar; 189(3):331-4. PubMed ID: 15792762
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
Hedner U
Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
[TBL] [Abstract][Full Text] [Related]
3. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
4. The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy.
McMullin NR; Kauvar DS; Currier HM; Baskin TW; Pusateri AE; Holcomb JB
Curr Surg; 2006; 63(4):246-51. PubMed ID: 16843774
[TBL] [Abstract][Full Text] [Related]
5. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
6. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
[TBL] [Abstract][Full Text] [Related]
7. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
[TBL] [Abstract][Full Text] [Related]
8. Pediatric off-label use of recombinant factor VIIa.
Alten JA; Benner K; Green K; Toole B; Tofil NM; Winkler MK
Pediatrics; 2009 Mar; 123(3):1066-72. PubMed ID: 19255041
[TBL] [Abstract][Full Text] [Related]
9. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation.
Loudon B; Smith MP
Intern Med J; 2005 Aug; 35(8):463-7. PubMed ID: 16176468
[TBL] [Abstract][Full Text] [Related]
11. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Bowman LJ; Uber WE; Stroud MR; Christiansen LR; Lazarchick J; Crumbley AJ; Kratz JM; Toole JM; Crawford FA; Ikonomidis JS
Ann Thorac Surg; 2008 May; 85(5):1669-76; discussion 1676-7. PubMed ID: 18442563
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
Raivio P; Suojaranta-Ylinen R; Kuitunen AH
Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
[TBL] [Abstract][Full Text] [Related]
13. Dosing with recombinant factor viia based on current evidence.
Hedner U
Semin Hematol; 2004 Jan; 41(1 Suppl 1):35-9. PubMed ID: 14872419
[TBL] [Abstract][Full Text] [Related]
14. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
[TBL] [Abstract][Full Text] [Related]
15. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage.
Bowles KM; Callaghan CJ; Taylor AL; Harris RJ; Pettigrew GJ; Baglin TP; Park GR
Br J Anaesth; 2006 Oct; 97(4):476-81. PubMed ID: 16914465
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
17. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association.
Knudson MM; Cohen MJ; Reidy R; Jaeger S; Bacchetti P; Jin C; Wade CE; Holcomb JB
J Am Coll Surg; 2011 Jan; 212(1):87-95. PubMed ID: 21115374
[TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VII in cardiac surgery: single-center experience.
Singh SP; Chauhan S; Choudhury M; Malik V; Choudhary SK
Asian Cardiovasc Thorac Ann; 2014 Feb; 22(2):148-54. PubMed ID: 24585784
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
Ganguly S; Spengel K; Tilzer LL; O'neal B; Simpson SQ
Clin Lab Haematol; 2006 Oct; 28(5):309-12. PubMed ID: 16999720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
